Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B007 Versus Cyclosporine in Primary Membranous Nephropathy
NCT06470191Phase 3Recruiting
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of B007 in primary membranous nephropathy (PMN), sponsored by Shanghai Cross-linked Pharmaceutical Research and Development. Started Jul 2024; status: recruiting.
02
Drugs
B007
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06470191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470191.